JP2015524408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524408A5 JP2015524408A5 JP2015523158A JP2015523158A JP2015524408A5 JP 2015524408 A5 JP2015524408 A5 JP 2015524408A5 JP 2015523158 A JP2015523158 A JP 2015523158A JP 2015523158 A JP2015523158 A JP 2015523158A JP 2015524408 A5 JP2015524408 A5 JP 2015524408A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- mammal
- pharmaceutical preparation
- cells
- preparation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000124008 Mammalia Species 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 206010011878 Deafness Diseases 0.000 claims 4
- 208000016354 hearing loss disease Diseases 0.000 claims 4
- 231100000888 hearing loss Toxicity 0.000 claims 3
- 230000010370 hearing loss Effects 0.000 claims 3
- 230000003834 intracellular effect Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 claims 1
- 108091005770 SIRT3 Proteins 0.000 claims 1
- 102000000478 Sirtuin 3 Human genes 0.000 claims 1
- 206010070863 Toxicity to various agents Diseases 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 231100000895 deafness Toxicity 0.000 claims 1
- 210000000959 ear middle Anatomy 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000000067 inner hair cell Anatomy 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 235000020956 nicotinamide riboside Nutrition 0.000 claims 1
- 239000011618 nicotinamide riboside Substances 0.000 claims 1
- 230000004792 oxidative damage Effects 0.000 claims 1
- 239000011814 protection agent Substances 0.000 claims 1
- 210000004116 schwann cell Anatomy 0.000 claims 1
- 210000001323 spiral ganglion Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261672169P | 2012-07-16 | 2012-07-16 | |
| US61/672,169 | 2012-07-16 | ||
| PCT/US2013/050511 WO2014014828A1 (en) | 2012-07-16 | 2013-07-15 | Nicotinamide riboside to treat hearing loss |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524408A JP2015524408A (ja) | 2015-08-24 |
| JP2015524408A5 true JP2015524408A5 (enExample) | 2016-09-08 |
| JP6289460B2 JP6289460B2 (ja) | 2018-03-07 |
Family
ID=49949192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015523158A Expired - Fee Related JP6289460B2 (ja) | 2012-07-16 | 2013-07-15 | 難聴を治療するためのニコチンアミドリボシド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9861651B2 (enExample) |
| EP (1) | EP2872128B1 (enExample) |
| JP (1) | JP6289460B2 (enExample) |
| ES (1) | ES2785303T3 (enExample) |
| WO (1) | WO2014014828A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007061798A2 (en) | 2005-11-18 | 2007-05-31 | Cornell Research Foundation, Inc. | Nicotinoyl riboside compositions and methods of use |
| RU2016149767A (ru) | 2014-06-06 | 2018-07-16 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Аналоги никотинамидрибозида и фармацевтические композиции и их применение |
| CA2956163C (en) | 2014-07-24 | 2023-01-10 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| ES2963057T3 (es) | 2015-03-09 | 2024-03-25 | Grace W R & Co | Forma cristalina de ribósido de nicotinamida |
| SI3297628T1 (sl) | 2015-05-18 | 2021-10-29 | Sensorion | Azasetron za uporabo pri zdravljenju izgube sluha |
| WO2017011788A1 (en) | 2015-07-15 | 2017-01-19 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
| US9855289B2 (en) | 2015-08-05 | 2018-01-02 | Metro International Biotech, Llc | Nicotinamide mononucleotide derivatives and their uses |
| GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
| HRP20240453T1 (hr) | 2016-04-14 | 2024-06-21 | Sensorion | (+)-azasetron za uporabu u liječenju poremećaja uha |
| US10576125B2 (en) | 2016-10-31 | 2020-03-03 | Hough Ear Institute | Methods for enhancing synaptogenesis and neuritogenesis |
| NZ803738A (en) | 2016-11-11 | 2024-05-31 | Chromadex Inc | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
| EP3554285A4 (en) | 2016-11-29 | 2021-01-20 | University of Iowa Research Foundation | USE OF NAD PRECURSORS TO IMPROVE THE HEALTH OF MOTHER AND / OR OFFspring |
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| US20190328761A1 (en) | 2016-12-21 | 2019-10-31 | Newsouth Innovations Pty Limited | Methods for enhancing vascular density |
| AU2018250242B2 (en) | 2017-04-05 | 2021-07-15 | Cornell University | Beta-nicotinate ester nucleotides and processes for preparing same |
| EP3727400A4 (en) | 2017-12-22 | 2021-10-20 | Elysium Health, Inc. | CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE |
| WO2019152416A1 (en) | 2018-01-30 | 2019-08-08 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
| US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
| US10618927B1 (en) | 2019-03-22 | 2020-04-14 | Metro International Biotech, Llc | Compositions and methods for modulation of nicotinamide adenine dinucleotide |
| JP7675061B2 (ja) | 2019-07-19 | 2025-05-12 | バイオシント アクチェンゲゼルシャフト | ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用 |
| CA3219033A1 (en) | 2021-05-27 | 2022-12-01 | Metro International Biotech, Llc | Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use |
| EP4727544A2 (en) | 2023-06-14 | 2026-04-22 | Chromadex Inc. | Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH695593A5 (de) | 2002-12-17 | 2006-06-30 | Granite Trading Ltd | Vorsatzlinse. |
| US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| AU2006269459B2 (en) | 2005-07-07 | 2013-02-07 | Sirtris Pharmaceuticals, Inc. | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| WO2009132050A2 (en) * | 2008-04-21 | 2009-10-29 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
-
2013
- 2013-07-15 EP EP13820653.7A patent/EP2872128B1/en active Active
- 2013-07-15 WO PCT/US2013/050511 patent/WO2014014828A1/en not_active Ceased
- 2013-07-15 JP JP2015523158A patent/JP6289460B2/ja not_active Expired - Fee Related
- 2013-07-15 ES ES13820653T patent/ES2785303T3/es active Active
- 2013-07-15 US US14/414,924 patent/US9861651B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2469726C2 (ru) | Композиции с контролируемым высвобождением на основе кортикостероидов для лечения ушных болезней | |
| MX357540B (es) | Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna. | |
| EA201692257A2 (ru) | Паразитицидные пероральные ветеринарные композиции, включающие системно действующие активные агенты, способы и применение этих композиций и способов | |
| NZ604029A (en) | Methods of treating bladder cancer | |
| CY1110495T1 (el) | Χρηση ενος αγωνιστη υποδοχεα nmda για τη θεραπεια εμβοης που προκαλειται απο κοχλιακη διεγερτοτοξικοτητα | |
| EA201190219A1 (ru) | Способы и композиции для лечения ишемических состояний и состояний, связанных с функцией митохондрий | |
| NZ611868A (en) | Gastric and colonic formulations and methods for making and using them | |
| FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
| JP2014511892A5 (enExample) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| NZ603985A (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
| WO2010011609A3 (en) | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | |
| JP2013530127A5 (enExample) | ||
| WO2009052411A3 (en) | Methods for treatment of thiol-containing compound deficient conditions | |
| UA107103C2 (uk) | Нікотиновмісні м'які желатинові пастилки | |
| HK1198869A1 (en) | Combination treatments for hepatitis c | |
| Uchida et al. | The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets | |
| EA201401231A1 (ru) | Фармацевтические комбинации, предназначенные для лечения метаболических нарушений | |
| BR112021025701A2 (pt) | Formulações e métodos de parasiticida de isoxazolina para tratar blefarite | |
| JP2020505432A5 (enExample) | ||
| MX2016002408A (es) | Metodos para el tratamiento de trastornos oticos pediatricos. | |
| Kang et al. | Effect of high dose intravenous vitamin C on idiopathic sudden sensorineural hearing loss: a prospective single-blind randomized controlled trial | |
| EA201270192A1 (ru) | Композиции и способы применения для пострадиационной защиты | |
| BR112014026184A2 (pt) | composições parasiticídicas compreendendo derivados de benzimidazol, métodos e seus usos | |
| RU2016103098A (ru) | Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii |